Why is irinotecan not used in adjuvant chemotherapy for resected colon cancer?

Why Irinotecan is Not Used in Adjuvant Chemotherapy for Resected Colon Cancer

Irinotecan should not be used in adjuvant chemotherapy for resected colon cancer because multiple large randomized trials have demonstrated no survival benefit while significantly increasing toxicity, including treatment-related deaths. 1, 2, 1

Evidence from Clinical Trials

Bolus Irinotecan Regimens (IFL)

The CALGB 89803 trial definitively established that irinotecan has no role in adjuvant therapy for stage III colon cancer 1, 3:

• No improvement in overall survival (P = 0.74) or disease-free survival (P = 0.84) compared to 5-FU/leucovorin alone 1, 3
• Significantly increased toxicity, including greater neutropenia, neutropenic fever, and treatment-related deaths 1, 3
• The trial was prematurely closed due to elevated mortality rates in the irinotecan arm (2.2% vs 0.8%) 3

Infusional Irinotecan Regimens (FOLFIRI)

FOLFIRI has similarly failed to demonstrate superiority over fluoropyrimidine therapy alone in the adjuvant setting 1:

• The PETACC-3 trial showed no significant advantage for irinotecan-containing regimens in terms of disease-free survival 4
• Multiple guidelines explicitly state that FOLFIRI has not been shown to be superior to 5-FU/leucovorin 1

Guideline Recommendations

All major guidelines uniformly recommend against irinotecan use in adjuvant therapy 1, 2, 1:

• NCCN Guidelines explicitly state: "Bolus 5-FU/leucovorin/irinotecan should not be used in adjuvant therapy and infusional 5-FU/leucovorin/irinotecan (FOLFIRI) has not been shown to be superior to 5-FU/leucovorin" 1
• "Bevacizumab, cetuximab, panitumumab, or irinotecan should not be used in the adjuvant setting for patients with stage II or III disease outside the setting of a clinical trial" 2, 1, 2

Contrast with Metastatic Disease

This represents a critical disconnect between metastatic and adjuvant settings 3, 5, 6:

• In metastatic colorectal cancer, irinotecan demonstrates clear survival benefits both as second-line therapy and when added to first-line 5-FU/leucovorin 3, 6
• In the adjuvant setting, these benefits completely disappear, demonstrating that advances in metastatic disease treatment do not automatically translate to the adjuvant setting 3, 5

Approved Indication

The FDA label for irinotecan specifically indicates its use only for metastatic carcinoma of the colon or rectum 7:

• First-line therapy in combination with 5-FU/leucovorin for metastatic disease 7
• Second-line therapy for metastatic disease that has progressed after initial fluorouracil-based therapy 7
• No FDA approval exists for adjuvant use in resected colon cancer 7

Current Standard of Care

Instead of irinotecan, the established adjuvant regimens are 1:

• FOLFOX or CapeOx (fluoropyrimidine plus oxaliplatin) for stage III disease (Category 1 recommendation) 1
• Single-agent capecitabine or 5-FU/leucovorin for patients unsuitable for oxaliplatin 1
• Oxaliplatin-based regimens have demonstrated clear disease-free survival benefits, unlike irinotecan 1

Common Pitfall

The most important pitfall is assuming that efficacy in metastatic disease predicts efficacy in the adjuvant setting 3, 5. This trial demonstrates the critical need for randomized controlled adjuvant studies rather than extrapolating from metastatic disease results 3.